INTRODUCTION
Tissue factor, the lipid-dependent protein which initiates the extrinsic system of coagulation, appears Dr. Rick was a fellow of the Helen Hay Whitney Foundation during the performance of these studies.
Received for publication 30 August 1976 and in revised form 3 January 1977. to reside between the surface coat and plasma membrane of a variety of mammalian cells, including fibroblasts (1-3), granulocytes (4, 5) , mononuclear cells (6) (7) (8) (9) (10) , and endothelial cells (11) (12) (13) . Unperturbed cells manifest little, if any, tissue factor activity, and "activation" by endotoxin, antigens, mitogens, or enzymes is required for expression of latent coagulant activity (3, 6) . A central role has been suggested for white cell tissue factor in the initiation of intravascular coagulation secondary to progranulocytic leukemia (14) (15) (16) and Gram-negative sepsis (17) (18) (19) (20) . Recent evidence has also suggested that tissue factor activity generated by immunocompetent cells may play a role in the deposition of fibrin seen in association with delayed hypersensitivity reactions (21, 22) . Specific or nonspecific activation of cell-bound tissue factor may be important, therefore, in the pathogenesis of both intravascular and extravascular coagulation.
Maynard and his colleagues (3) have demonstrated that trypsin, chymotrypsin, pronase, papain, and a bacterial protease activate tissue factor in fibroblasts and cells derived from human amnion tissue. They have interpreted these findings to mean that the latency of tissue factor activity may represent a protective mechanism. In this way, tissue factor can be in proximity to flowing blood for use in the defense against trauma without producing intravascular coagulation. The mechanism of this activation reaction and the step or steps involved, therefore, become of central importance to the understanding of hemostasis and thrombosis.
teria is a potent activator of tissue factor when introduced into suspensions of leukocytes (4, 5, (8) (9) (10) (17) (18) (19) (20) . The multiple biologic properties of LPS obtained from a variety of microorganisms are well known and have recently been reviewed (23, 24 Wild-type Salmonella typhimurium LT-2 has been previously described (29) . Strain G30 is a mutant of S. typhimurium LT-2 which lacks the enzyme UDP-galactose-4-epimerase (29 (33, 35) . Briefly, lipid A (2 mg) in water (1.0 ml) was solubilized by addition of triethylamine (10 ,ul) as reference standards (25) . Polymyxin B-treated LPS was prepared as described by Jacobs and Morrison (37) and utilized in tissue culture after ovemight dialysis against pyrogen-free water or, polymyxin B itself (Aerosporin, Burroughs Wellcome Co., Research Triangle Park, N. C.) was added, uncomplexed, to LPS-stimulated cultures to achieve a final concentration of10,ug/ml. All materials were handled with pyrogen-free plastic pipettes (Falcon Plastics, Oxnard, Calif.) and serial log-dilutions of LPS (10 ,ug/ml to 10-5 ,g/ml) were made in pyrogen-free plastic tubes (Falcon Plastics), 
RESULTS
Lipopolysaccharides isolated from Re (G30-A) and R, (G30) mutants of S. typhimurium lack all portions of the polysaccharide region distal to the KDO residues and the first glucose residue, respectively (Fig. 2  B and C) . The LPS molecules isolated from these mutants proved capable of activating tissue factor in cultures of human mononuclear cells (Fig. 3) . Although the dose-response curve revealed statistically significant differences in the activity ofthese polymers, LPS from the heptoseless mutant (G-30A) generated nearly as much tissue factor as wild-type LPS at the higher doses. These data suggest that the 0-antigen and outer core regions, as well as the heptosyl portion of the backbone region, are not required for the activation of tissue factor. This conclusion was supported by the fact that the polysaccharide portion of wild-type LPS, obtained by treatment of LPS with mild acid, failed to activate tissue factor in this system (Table I) . However, because of the acid lability of the KDO (23, 38, 39) .
In an attempt to alter the biological activity of LPS without modifying the covalent structure of the molecule, we examined the effects of the cyclic polypeptide antibiotic polymyxin B on this system. Polymyxin B is bactericidal for most Gram-negative bacteria, and it has been reported to prevent the lethal endotoxin activity of LPS (40) (41) (42) (43) (44) as well as to alter the physical structure of LPS (37, 45 myxin B (Fig. 5 ). However, activation by both heptoseless LPS (G30-A) and lipid A, although not abolished, was significantly decreased by preincubation with the antibiotic. The antibiotic alone had no effect on either the viability of the cultured cells (As determined by trypan blue exclusion) or the assay for tissue factor. At high LPS or lipid A concentrations, polymyxin B failed to completely inhibit the ability of these preparations to activate tissue factor. However, dose-response curves demonstrated that polymyxin B almost completely inhibited these preparations when they were present at lower concentrations (Fig. 6 ). This inhibitory effect could be demonstrated either by incubating polymyxin B with the cultured cells in the presence of the LPS preparation or by using LPS that had been pretreated with polymyxin B and from which excess antibiotic had been removed by exhaustive dialysis. Similar results were obtained when the LPS from the rough mutant S. minnesota R595 was substituted for the analagous LPS isolated from S. typhimurium G30-A.
DISCUSSION
Tissue factor is a potent procoagulant which may be important in the pathogenesis of intra-and extravascular coagulation in a variety of disorders (14) (15) (16) (17) (18) (19) (20) (21) (22) 46) . Recent evidence has suggested that tissue factor is present in cell membranes in an inactive form which is "activated" by an unknown mechanism as a result of the interaction of the cell with various agents (3, 6) . The location of tissue factor in the surface coat of endothelial cells and fibroblasts provides a ready source of procoagulant material for intravascular thrombus formation, while its presence in mononuclear cells (monocytes and lymphocytes) may explain the prominence of fibrin in many inflammatory disorders (22, 47, 48) . We have suggested that antigens or antigen-antibody complexes, such as those elaborated during the renal allograft rejection reaction, can activate mononuclear cell tissue factor (7). Alternatively, other stimuli such as LPS, which has been shown to activate tissue factor, may do so secondary to binding to cell membranes (49) (50) (51) . Characterization of this activation process, therefore, becomes important in order to assess the role of tissue factor in thrombosis and inflammation.
We have demonstrated previously (25) that activation of mononuclear cell tissue factor by LPS does not require DNA synthesis. In addition, we have confirmed the observation of Rivers et al. (9) that the bulk of the activity in the LPS-stimulated cultures is supplied by monocytes although we demonstrated that B-type lymphycytes are also active. T cells appear to lack the ability to generate tissue factor activity (10) . In the current study we have focused our attention on the specific structural requirements for LPS activation of tissue factor. Inasmuch as LPS activation of tissue factor in a variety of cells may be important in the pathophysiology of disseminated intravascular coagulation associated with Gram-negative sepsis (17) (18) (19) (20) , further characterization of the properties of LPS necessary for this biological role seemed warranted. Fig. 2 B) ; G30A, LPS from the heptoseless mutant ( Fig. 2 C) ; lipid A, LPS after acid hydrolysis (see Methods and Fig. 2 D) . All preparations of LPS were tested at 1.0 ,ug/ml. A minimum of 15 paired experiments are represented by each set of bars (with and without PB) and a two-tailed student's t test was used to determine the significance of the differences between pairs. NS, not significant (P > 0.05).
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The evidence presented here clearly indicates that the lipid A region of Gram-negative LPS is the biologically active portion of the molecule required for the generation of tissue factor activity by human mononuclear cells. In support of this conclusion, we found that LPS molecules lacking the 0-antigen and much of the outer core and backbone regions (Fig. 2 (52) . In addition, the conversion of lipid A to a more hydrophilic molecule by alkali may result in the alteration of physical properties of this glycolipid which are important for its biological activity. However, the specific structural or physiochemical properties of lipid A required for biological activity are not known.
Recent studies by Nowotny et al. (53) indicated that the polysaccharide fraction obtained by mild acid hydrolysis of S. minnesota LPS is active in the stimulation of mouse bone marrow cell colony formation and in the protection of mice against lethal irradiation. Lipid A preparations were found by these investigators to be either much less active or completely inactive in the above two assays. In addition, Morrison et al. (54) have reported that the polysaccharide portion of LPS plays an important role in the activation of the alternative pathway of complement. However, to our knowledge, these reports are the first to attribute in vivo biological activity to portions of the LPS molecule other than the lipid A region.
Similar dissociations of the properties of LPS have been demonstrated after interaction with the cyclic peptide antibiotic, polymyxin B, in vitro (37, (40) (41) (42) (43) (44) (45) . Polymyxin B-treated LPS, though no longer mitogenic (37) nor anticomplementary (45) , still retains its ability to generate an immune response when complexed with a hapten (37) . As demonstrated in Inhibition of tissue factor generation by polymyxin B was as follows: (a) wild-type (whole) LPS-45% at 0.01 ug/ml and 100% at 0.0001 ,ug/ml and 0.000001 ,ug/ml; (b) G30-A-28% at 1.0,ug/ml, 30% at 0.1 Ag/ml, 73% at 0.01 ,ug/ml, and 100% at 0.0001 ,tglml; (c) lipid A-57% at 0.1 ,ug/ml, 93% at 0.01 ,ug/ml, and 100% at 0.0001 ,ug/ml. polymyxin B-treated whole LPS and G30 were still capable of activating tissue factor, but tissue factor generation in response to LPS obtained from the heptoseless mutant (G30-A) and lipid A was significantly reduced by polymyxin B, particularly when these LPS fractions were used at lower concentrations (Fig. 6) . Essentially complete inhibition of tissue factor activation was made possible when polymyxin B was added to lower concentrations of LPS or lipid A and subsequently reacted with the cells (Fig. 6) . Activation of Tissue Factor by S. Typhimurium Lipopolysaccharide 1193
Although our results with LPS preparations are compatible with the suggestion by Morrison and Jacobs (45) that LPS and polymyxin B form a stable molecular complex via binding to the lipid A-2-keto-3-deoxyoctulosonate region of LPS, the complete absence of KDO residues in our preparations of lipid A suggests that KDO is not necessary for the binding of polymyxin B to LPS. Recent evidence published by Morrison and his co-workers (55) and Sultzer and Goodman (56) suggests that LPS preparations are contaminated to varying degrees with a low molecular weight protein which prevents the binding of polymyxin B to the lipid A region. Hot phenol extraction appears to remove the putative protein and renders the resultant LPS susceptible to polymyxin B action. It is of interest that both groups of investigators have found the contaminant to be itself mitogenic for spleen cells from the C3H/HeJ strain of mice, whereas the resultant LPS after extraction is nonmitogenic, thus explaining disparate results from several laboratories using this genetically resistant strain of mice. It seems possible, therefore, that the contaminating protein, which copurifies with LPS, may be responsible for variable inhibition of LPS preparations by polymyxin B. Polymyxin B has been shown to prevent the development of the generalized Shwartzman reaction in rabbits and the subsequent development of disseminated intravascular coagulation (42, 43) . Niemetz and others (17) (18) (19) have suggested that leukocyte tissue factor plays a central role in the mediation of this lesion, and it is conceivable, therefore, that the inhibitory activity of polymyxin B demonstrated in vitro in our experiments accounts for some of the protective effect of the antibiotic in vivo (43) .
The understanding of the activation of tissue factor on the surface of a variety of cells, therefore, may be enhanced by further evaluation of the interaction of the lipid A moiety of LPS with mononuclear cell membranes. Experiments are also in progress to evaluate the role of the LPS-related protein (55) (56) (57) in the activation of tissue factor.
